NCT06566391 2024-08-22
Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma
European Institute of Oncology
Phase 2 Unknown
Clinical Trials
17 trialsNCT03818685 2024-02-12
BreastImmune03
Centre Leon Berard
Phase 2 Unknown
NCT03146650 2024-01-18
Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer
Northwestern University
Phase 2 Unknown
NCT05150236 2023-12-15
ANZUP2001
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Unknown
NCT02977052 2023-11-15
OpACIN-neo
The Netherlands Cancer Institute
Phase 2 Unknown
NCT03097939 2023-10-11
Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma
National Cancer Centre, Singapore
Phase 2 Unknown
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT03528408 2023-04-11
Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma
Hoosier Cancer Research Network
Phase 2 Unknown
NCT04571632 2022-09-14
Luscid
Universitair Ziekenhuis Brussel
Phase 2 Unknown
NCT04575922 2022-09-08
Nivolumab+Ipilimumab+RT in MSS mCRC
Massachusetts General Hospital
Phase 2 Unknown
NCT03219775 2021-11-03
TITAN-TCC
AIO-Studien-gGmbH
Phase 2 Unknown
NCT04134182 2020-12-23
Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.
Kidney Cancer Research Bureau
Phase 2 Unknown
NCT04131621 2020-04-15
CheCUP
University Hospital Heidelberg
Phase 2 Unknown
NCT03823625 2020-03-25
SQUINT
Fondazione Ricerca Traslazionale
Phase 2 Unknown
NCT04250246 2020-01-31
NIBIT-ML1
Italian Network for Tumor Biotherapy Foundation
Phase 2 Unknown
NCT02982486 2017-11-01
A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma
Assaf-Harofeh Medical Center
Phase 2 Unknown
NCT01565837 2016-02-01
SART
Comprehensive Cancer Centers of Nevada
Phase 2 Unknown